T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents
A Phase I/II Pharmacokinetic and Safety Study of T-20 in Combination With an Optimized Background in HIV Infected Children and Adolescents
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hosp Los Angeles
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Univ of Florida Gainesville
-
-
New York
-
Bronx, New York, United States, 10461
- Bronx Municipal Hosp Ctr/Jacobi Med Ctr
-
Bronx, New York, United States, 10457
- Bronx Lebanon Hosp Ctr
-
New York, New York, United States, 10021
- New York Hosp - Cornell / Program for Children with AIDS
-
New York, New York, United States, 10029
- Mount Sinai Hosp
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Children's Hosp of the King's Daughters
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Patients may be eligible for this study if they:
- Are 3 through 16 years of age and have the consent of parent or guardian.
- Have a viral load of at least 5000 copies/ml.
- Have taken at least 2 of the 3 licensed anti-HIV drug classes for at least 3 months.
- Have been on stable therapy for at least 4 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Plasma Concentration Time Curve (AUC) From 0-12 Hours for Enfuvirtide and Its Metabolite (Ro 50-6343)
Time Frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
|
The Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time.
It is used to characterize drug absorption.
AUC was calculated from plasma concentration-time data (on Day 7) using standard non-compartmental pharmacokinetic methods.
|
Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Plasma Concentration (Cmax) for Enfuvirtide and Its Metabolite (Ro 50-6343)
Time Frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
|
The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration.
Cmax was calculated from plasma concentration-time data (on Day 7) using standard non-compartmental pharmacokinetic methods.
|
Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
|
|
Time to Maximum Plasma Concentration (Tmax) for Enfuvirtide
Time Frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
|
Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
|
Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
|
|
Minimum Plasma Concentration (Ctrough) for Enfuvirtide and Its Metabolite (Ro 50-6343)
Time Frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
|
Ctrough is defined as the lowest concentration that a drug reaches before the next dose is administered.
|
Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
|
|
AUC12h Ratio of Enfuvirtide Metabolite (Ro 50-6343)/ENF (Ro 29-9800)
Time Frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
|
The ratio of the area under plasma concentration-time curve from time 0 to 12 hours of Enfuvirtide Metabolite (Ro 50-6343) versus enfuvirtide was calculated.
|
Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)
|
|
Number of Participants With Adverse Events (AEs) and Serious AEs
Time Frame: Up to Week 4 after discontinuation of therapy
|
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event.
|
Up to Week 4 after discontinuation of therapy
|
|
Number of Participants With Treatment Emergent Grade 3 or Grade 4 Laboratory Abnormalities
Time Frame: Up to Week 96
|
Pediatric AIDS Clinical Trials Group (PACTG) toxicity grading scale was used for reviewing and grading clinically significant laboratory abnormalities.
PACTG Grade 3 and Grade 4 were considered Severe and life threatening, respectively.
|
Up to Week 96
|
|
Number of Participants Who Died
Time Frame: Up to Week 96
|
Up to Week 96
|
|
|
Number of Participants Who Prematurely Withdrew Due to AE
Time Frame: Up to Week 96
|
Up to Week 96
|
|
|
Number of Participants With Worst Local Injection Site Reactions
Time Frame: Up to Week 96
|
Numbers of Participants With worst local injection site reactions were reported.
Localized injection site reactions like erythema, induration, pruritus, nodule and cyst, and ecchymosis were recorded.
|
Up to Week 96
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Fusion Inhibitors
- Viral Fusion Protein Inhibitors
- Enfuvirtide
Other Study ID Numbers
Other Study ID Numbers
- NV16056
- T20-310
- 295E
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.